These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 7458408

  • 1. Biochemical and immunological studies of fibroblasts derived from a patient with Ehlers-Danlos syndrome type IV. Demonstrate reduced type III collagen synthesis.
    Aumailley M, Krieg T, Dessau W, Müller PK, Timpl R, Bricaud H.
    Arch Dermatol Res; 1980; 269(2):169-77. PubMed ID: 7458408
    [Abstract] [Full Text] [Related]

  • 2. Low production of procollagen III by skin fibroblasts from patients with Ehlers-Danlos syndrome type IV is not caused by decreased levels of procollagen III mRNA.
    Aumailley M, Pöschl E, Martin GR, Yamada Y, Müller PK.
    Eur J Clin Invest; 1988 Apr; 18(2):207-12. PubMed ID: 3133227
    [Abstract] [Full Text] [Related]

  • 3. Simultaneous synthesis of types I and III collagen by fibroblasts in culture.
    Gay S, Martin GR, Muller PK, Timpl R, Kuhn K.
    Proc Natl Acad Sci U S A; 1976 Nov; 73(11):4037-40. PubMed ID: 1069290
    [Abstract] [Full Text] [Related]

  • 4. Low levels of serum type III procollagen aminoterminal propeptide confirmed type III collagen deficiency in patients without typical clinical symptoms of Ehlers-Danlos type IV.
    Dyne KM, Zanaboni G, Annoni G, De Agostini MP, Cetta G.
    Eur J Clin Invest; 1989 Aug; 19(4):362-6. PubMed ID: 2506053
    [Abstract] [Full Text] [Related]

  • 5. Ehlers-Danlos syndrome type VIII: biochemical, stereological and immunocytochemical studies on dermis from a child with clinical signs of Ehlers-Danlos syndrome and a family history of premature loss of permanent teeth.
    Dyne KM, Vitellaro-Zuccarello L, Bacchella L, Lanzi G, Cetta G.
    Br J Dermatol; 1993 Apr; 128(4):458-63. PubMed ID: 8494762
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Synthesis of an altered type III procollagen in a patient with type IV Ehlers-Danlos syndrome. A structural change in the alpha 1(III) chain which makes the protein more susceptible to proteinases.
    Stolle CA, Pyeritz RE, Myers JC, Prockop DJ.
    J Biol Chem; 1985 Feb 10; 260(3):1937-44. PubMed ID: 2981879
    [Abstract] [Full Text] [Related]

  • 13. Patients with Ehlers-Danlos syndrome type IV lack type III collagen.
    Pope FM, Martin GR, Lichtenstein JR, Penttinen R, Gerson B, Rowe DW, McKusick VA.
    Proc Natl Acad Sci U S A; 1975 Apr 10; 72(4):1314-6. PubMed ID: 1055406
    [Abstract] [Full Text] [Related]

  • 14. Defect in conversion of procollagen to collagen in a form of Ehlers-Danlos syndrome.
    Lichtenstein JR, Martin GR, Kohn LD, Byers PH, McKusick VA.
    Science; 1973 Oct 19; 182(4109):298-300. PubMed ID: 4742738
    [Abstract] [Full Text] [Related]

  • 15. Ehlers-Danlos syndrome. A variant characterized by the deficiency of pro alpha 2 chain of type I procollagen.
    Sasaki T, Arai K, Ono M, Yamaguchi T, Furuta S, Nagai Y.
    Arch Dermatol; 1987 Jan 19; 123(1):76-9. PubMed ID: 3800425
    [Abstract] [Full Text] [Related]

  • 16. Molecular defects in the Ehlers-Danlos syndrome.
    Pinnell SR.
    J Invest Dermatol; 1982 Jul 19; 79 Suppl 1():90s-92s. PubMed ID: 7086195
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The mRNA and the activity of lysyl hydroxylase are up-regulated by the administration of ascorbate and hydralazine to human skin fibroblasts from a patient with Ehlers-Danlos syndrome type VI.
    Yeowell HN, Walker LC, Marshall MK, Murad S, Pinnell SR.
    Arch Biochem Biophys; 1995 Aug 20; 321(2):510-6. PubMed ID: 7646078
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.